AstraZeneca (LON:AZN) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

by · The Cerbat Gem

AstraZeneca PLC (LON:AZN – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £141.38 and traded as high as £145.66. AstraZeneca shares last traded at £144.56, with a volume of 649,606 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on AZN shares. Citigroup lifted their price objective on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research note on Friday, April 10th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and set a £115 target price on shares of AstraZeneca in a research note on Friday, June 26th. Finally, Jefferies Financial Group restated a “buy” rating and set a £180 target price on shares of AstraZeneca in a report on Friday, June 26th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of £153.33.

Get Our Latest Stock Report on AZN

AstraZeneca Stock Down 0.6%

The business’s fifty day moving average is £137.36 and its two-hundred day moving average is £141.38. The stock has a market cap of £224.19 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 0.86 and a beta of 0.21. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Articles